A classification of clinical scenarios into three buckets: patients where LH is non-negotiable, patients where it almost is, and patients where the cycle can be run without it. Built on the two-cell two-gonadotrophin model, with examples spanning hypogonadotrophic hypogonadism, LHCGR polymorphism carriers, advanced reproductive age and prior protocol failure.
Bucket 1 (LH essential): hypogonadotrophic hypogonadism, Kallmann syndrome, post-pituitary surgery — without LH there is no steroidogenesis and no follicular maturation. Bucket 2 (LH almost essential): advanced reproductive age with low LH:FSH ratio, specific LHCGR polymorphisms, prior cycles with low oocyte maturity. Bucket 3 (LH optional): young patients with intact axis, first cycle, no prior failure. LH activity and HCG are not biologically equivalent.
Use the three-bucket map to decide on LH supplementation before the first stimulation cycle. Reserve recombinant LH for buckets 1 and 2; pure FSH protocol can be the first-line for bucket 3. Re-classify after the first cycle based on maturity, fertilisation and embryo development.
Bucket boundaries are not absolute — patient phenotype and prior cycle data shift the classification. LH supplementation has cost; reserve it for cases where physiology predicts a measurable difference. HMG, recombinant LH and HCG cover different parts of LH activity and are not interchangeable.
LH-receptor polymorphisms create a 'hidden' form of deficiency: the gonadotropin is normal on lab tests, but the receptor responds poorly. Clinically this looks like an inexplicably poor response or low estradiol despite an adequate FSH dose — a reason to suspect a receptor cause.
The two-cell, two-gonadotropin model explains why LH is irreplaceable: FSH drives granulosa aromatase, but its substrate is provided only by LH-dependent androgen synthesis in the theca. This link cannot be broken — estrogenesis requires both gonadotropins.
Recombinant LH and hCG have different kinetics: LH acts briefly and physiologically, hCG longer and more potently owing to prolonged receptor binding. The choice between them is determined by the task — fine support of steroidogenesis or a strong final stimulus.
The conclusion is a decision tree for prescribing recombinant LH: hypogonadotropic hypogonadism, age 35+, relative LH deficiency, a poor previous response, suspicion of receptor pathology. In these scenarios LH moves from a 'desirable' to a 'necessary' component of the protocol.
Three buckets of patients: those where LH is non-negotiable, those where it almost is, and those where you can manage without. The talk classifies clinical scenarios — hypogonadotrophic hypogonadism, LH receptor polymorphisms, advanced reproductive age — and gives a decision tree for when recombinant LH actually changes the cycle outcome.
-1.png&w=3840&q=75)
